← All indications
Central Serous Chorioretinopathy
A visual impairment characterized by the accumulation of fluid under the retina through a defect in the retinal pigment epithelium.
Drugs by status
Approved for this indication (1)
Phase 4 trials (2)
Phase 3 trials (4)
Phase 2 trials (20)
Phase 1 trials (3)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (19)
- Regeneron
- Alcon
- Novartis
- The EMMES Corporation
- National Eye Institute (NEI)
- Bay Area Retina Associates
- Manhattan Eye, Ear & Throat Hospital
- Ophthalmic Consultants of Boston
- Seoul National University
- Tufts University
- Thomas Jefferson University
- Columbia University
- Prince of Songkla University
- Tel Aviv University
- University of Ulsan
- University of Tabriz
- Hebrew University
- Tabriz Medical University
- LuEsther T. Mertz Retinal Research Center
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (4)